State of anti-rubella virus population immunity in the Republic of Belarus and Russian Federation
- Authors: Tsvirkun O.V.1,2, Samoilovich E.O.3, Tikhonova N.T.4, Gerasimova A.G.4, Turaeva N.V.4, Ermolovich M.A.3, Semeiko G.V.3
-
Affiliations:
- .N. Gabrichevsky Research Institute for Epidemiology and Microbiology
- Peoples’ Friendship University of Russia
- Republican Research and Practical Center for Epidemiology and Microbiology
- G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
- Issue: Vol 12, No 5 (2022)
- Pages: 909-918
- Section: ORIGINAL ARTICLES
- URL: https://bakhtiniada.ru/2220-7619/article/view/119147
- DOI: https://doi.org/10.15789/2220-7619-COT-1832
- ID: 119147
Cite item
Full Text
Abstract
To confirm a progress towards the rubella elimination, immunization coverage indicators and the results of serological studies are used. At the same time, the most objective method of assessing collective immunity is a serological examination. The purpose of this work was to compare the results of assessing state of population immunity against rubella virus in the Republic of Belarus and the Russian Federation using various vaccines and different approaches to study organization and cohort selection — screening and monitoring. 2019 laboratory studies to determine IgG antibodies against rubella virus were carried out by ELISA method of the unified enzyme immunoassay system “Ecolab” (Russia). The serum study results of 701 subjects aged 2–45 years from all the 7 regions of the Republic of Belarus (screening study) and 55 082 subjects aged 3–49 years (monitoring) from 85 regions of the Russian Federation were analyzed. The results were evaluated in three age groups — children, adults, total cohort by using a threshold level of 83–85% seropositive individuals sufficient to prevent virus transmission. The antigenic composition of the rubella component in the mono- and complex vaccines respectively used in the Russian Federation and the Republic of Belarus is identical, which allows to compare the state of population immunity against rubella virus therein without taking into account an influence of the vaccine strain. Studies have shown that while using varying vaccine preparations and approaches to organization of serological examination, both in the Republic of Belarus and the Russian Federation, rubella virus-specific IgG level was detected at rather high level in all age groups comprising more than 90%. The portion of rubella seropositive subjects in entire country was 95.44% in the Republic of Belarus and 97.14% in the Russian Federation. Moreover, the level of specific antibodies remains high, despite the low incidence rate and absence of booster effect in both countries. The mean group antibody concentration in seropositive patients in all age groups was quite high and exceeded the minimum protective concentration (11 IU/ml) by 10 or more times. The data obtained indicate the legitimacy of using a serological study of collective rubella immunity as a routine or seromonitoring as well as periodic or screening investigation.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
O. V. Tsvirkun
.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Peoples’ Friendship University of Russia
Author for correspondence.
Email: o.tsvirkun@gabrich.ru
PhD, MD (Medicine), Head of the Epidemiology Department, Associate Professor, Department of Infectious Diseases with Courses in Epidemiology and Phthisiology
Russian Federation, Moscow; MoscowE. O. Samoilovich
Republican Research and Practical Center for Epidemiology and Microbiology
Email: esamoilovich@gmail.com
PhD, MD (Medicine), Professor, Head of the Laboratory of Vaccine Preventable Diseases
Belarus, MinskN. T. Tikhonova
G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
Email: tikhmail@mail.ru
PhD, MD (Biology), Professor, Head Researcher, Laboratory of Cytokines
Russian Federation, MoscowA. G. Gerasimova
G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
Email: 4521809@mail.ru
PhD (Medicine), Leading Researcher, Laboratory of Viral Infections Prophylaxis
Russian Federation, MoscowN. V. Turaeva
G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
Email: natalya-turaeva@yandex.ru
PhD (Medicine), Head of the Laboratory for Viral Infections Prevention
Russian Federation, MoscowM. A. Ermolovich
Republican Research and Practical Center for Epidemiology and Microbiology
Email: yermalovich@mail.ru
PhD, MD (Medicine), Head Researcher, Laboratory of Vaccine Preventable Diseases
Belarus, MinskG. V. Semeiko
Republican Research and Practical Center for Epidemiology and Microbiology
Email: g-semeiko@yandex.ru
PhD (Biology), Leading Researcher, Laboratory of Vaccine Preventable Diseases
Belarus, MinskReferences
- О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. [On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2019: state report. (In Russ.)] URL: https://www.rospotrebnadzor.ru/upload/iblock/8e4/gosdoklad-za-2019_seb_29_05.pdf (03.11.2021)
- Самойлович Е.О. Надзор за вакциноуправляемыми инфекциями в Республике Беларусь: соответствие международным стандартам // Здравоохранение. 2014. № 6. С. 7–11. [Samoilovich E.O. Surveillance of vaccine-preventable infections in the Republic of Belarus: compliance with international standards. Zdravookhranenie = Healthcare, 2014, no. 6, pp. 7–11. (In Russ.)]
- Самойлович Е.О., Свирчевская Е.Ю., Ермолович М.А., Семейко Г.В. Популяционный иммунитет к краснухе в Республике Беларусь в 2011 г. // Современные проблемы инфекционной патологии человека: сб. науч. тр. Минск: ГУ РНМБ, 2012. Вып. 5. С. 261–264. [Samoilovich E.O., Svirchevskaya E.Yu., Yermolovich M.A., Semeiko G.V. Heard immunity to rubella in the Republic of Belarus in 2011. In: Modern problems of human infectious pathology: collection of scientific works. Minsk: RSML, 2012. Iss. 5, pp. 261–264. (In Russ.)]
- Семейко Г.В., Самойлович Е.О., Ермолович М.А., Свирчевская Е.Ю. Краснуха в Республике Беларусь в 2016–2019 гг. // Современные проблемы инфекционной патологии человека: сб. науч. тр.; под ред. В.А. Горбунова. Минск: СтройМедиаПроект, 2019. Вып. 12. С. 74–77. [Semeiko G.V., Samoilovich E.O., Yermolovich M.A., Svirchevskaya E.Yu. Rubella in the Republic of Belarus in 2016–2019. Modern problems of human infectious pathology: collection of scientific works. Ed. V.A. Gorbunov. Minsk: StroyMediaProekt, 2019. Iss. 12, pp. 74–77. (In Russ.)]
- Таточенко В.К., Озерецковский Н.А. Вакцинопрофилактика-2018: справочник. 13-е изд., расширенное. М.: ООО «МСД Фармасьютикалс», 2018. 268 c. [Tatochenko V.K., Ozeretskovsky N.A. Vaccinoprophylaxis-2018, handbook, 13th ed., expanded. Moscow: LLC “MSD Pharmaceuticals”, 2018. 268 p. (In Russ.)]
- Bianchi F.P., De Nitto S., Stefanizzi P., Larocca A.M.V., Germinario C.A., Tafuri S. Immunity to rubella: an Italian retrospective cohort study. BMC Public Health, 2019, vol. 19, no. 1: 1490. doi: 10.1186/s12889-019-7829-3
- Borràs E., Campins M., Esteve M., Urbiztondo L., Broner S., Bayas J.M., Costa J., Domínguez A.; Working Group for the Study of the Immune Status in Healthcare Workers. Are healthcare workers immune to rubella? Hum. Vaccin. Immunother., 2014, vol. 10, no. 3, pp. 686–691. doi: 10.4161/hv.27498
- Coppeta L., Ferrari C., Iannuzzi I., D’Alessandro I., Balbi O., Pietroiusti A., Trabucco Aurilio M. Rubella immunity among italian female healthcare workers: a serological study. Int. J. Environ. Res. Public Health, 2020, vol. 17, no. 21: 7992. doi: 10.3390/ijerph17217992
- Crooke S.N., Haralambieva I.H., Grill D.E., Ovsyannikova I.G., Kennedy R.B., Poland G.A. Seroprevalence and durability of rubella virus antibodies in a highly immunized population. Vaccine, 2019, vol. 37, no. 29, pp. 3876–3882. doi: 10.1016/j.vaccine.2019.05.049
- Dean A.G., Sullivan K.M., Soe M.M. OpenEpi: open source epidemiologic statistics for public health, Version. URL: http://www. OpenEpi.com
- Fine P.E.M., Mulholland K., Scott J.A., Edmunds W.J. Community protection. In: Plotkin’s Vaccines. Eds.: Orenstein W., Offit P., Edwards K.M., Plotkin S. Elsevier, 2018, pp. 1512–1531. doi: 10.1016/C2013-0-18914-3
- Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Goergen K.M., Grill D.E., Chen M.H., Hao L., Icenogle J., Poland G.A. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. Vaccine, 2020, vol. 38, no. 5, pp. 1249–1257. doi: 10.1016/j.vaccine.2019.11.004
- Hyde T.B., Kruszon-Moran D., McQuillan G.M., Cossen C., Forghani B., Reef S.E. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin. Infect. Dis., 2006, vol. 43, suppl. 3, pp. S146–S150. doi: 10.1086/505947
- Ogawa T., Inoue T., Kasahara K., Konishi M., Mikasa K. Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: an observational study. PLoS One, 2020, vol. 15, no. 3: e0230329. doi: 10.1371/journal.pone.0230329
- World Health Organization. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. Copenhagen, 2013. 19 p. URL: https://www.euro.who.int/__data/assets/pdf_file/0011/236648/Guidance-on-conducting-serosurveys-in-support-of-measles-and-rubella-elimination-in-the-WHO-European-Region.pdf (15.10.2021)
- World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome. Geneva, Switzerland: World Health Organization, 2018. 18 p. URL: https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-1.pdf?sfvrsn=f7f1fc1d_2&download=true (20.11.2020)
Supplementary files
